Universal Influenza Vaccines

Lidewij C. M. Wiersma , Guus F. Rimmelzwaan and Rory D. de Vries. (2015) Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccine 2015, 3(2), 239-262.

GFP expressing influenza A virus

Sarah De Baets, Judith Verhelst, Silvie Van den Hoecke, Anouk Smet, Michael Schotsaert, Emma R. Job, Kenny Roose, Bert Schepens, Walter Fiers, and Xavier Saelens. (2015) A GFP Expressing Influenza A Virus to Report In Vivo Tropism and Protection by … Continue reading

Long-lived CD8 T-cell response against influenza

van de Sandt CE, Hillaire ML, Geelhoed-Mieras MM, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. (2015) Human Influenza A Virus-Specific CD8+ T-Cell Response Is Long-lived. J Infect Dis. 2015 Jan 12. pii: jiv018. [Epub ahead of print]

Broad bispecific antibody against influenza virus

Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, Witte MD, van Zoelen DJ, Cornelissen LA, Beaumont T, Bakker AQ, Ploegh HL, Spits H. (2014) Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc Natl Acad Sci U S A. 111(47):16820-5

Promising results in the Journal of Infectious Diseases!

J.H.C.M. Kreijtz, L.C.M. Wiersma, H.L.M. Gruyter De, S.E. Vogelzang-van Trierum, G. van Amerongen, K.J. Stittelaar, R.A.M. Fouchier, A.D.M.E. Osterhaus, G. Sutter and G.F. Rimmelzwaan (2014) A single immunization with a modified Vaccinia Virus Ankara-based influenza virus H7 vaccine affords protection in … Continue reading

Review in Viruses

Arwen F. Altenburg, Joost H. C. M. Kreijtz, Rory D. de Vries, Fei Song, Robert Fux, Guus F. Rimmelzwaan, Gerd Sutter and Asisa Volz (2014) Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory … Continue reading

Publication in Journal of Virology

Asisa Volz, Martin Langenmayer, Sylvia Jany, Ulrich Kalinke and Gerd Sutter (2014) Rapid expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with Modified Vaccinia virus Ankara. Journal of Virology Published … Continue reading


FLUNIVAC aims at developing a candidate influenza vaccine based on recombinant Modified Vaccinia virus Ankara viruses (rMVA) encoding both B-cell and T- cell response-inducing proteins, ready to commence Phase I clinical trials. We focus on influenza A virus since it … Continue reading